Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1981 Dec;46(6):663–670. doi: 10.1136/hrt.46.6.663

Immediate and sustained haemodynamic effects of prazosin during upright exercise in man.

B Silke, W G Hendry, S H Taylor
PMCID: PMC482714  PMID: 7317235

Abstract

To ascertain the immediate pharmacodynamic and long-term haemodynamic effects of prazosin in chronic ambulant heart failure, measurements were made during sitting, standing, and walking in 12 patients with severe ischaemic left ventricular failure before and after their first dose of prazosin (2 mg) and in six of these patients after a further 12 weeks of sustained treatment (2 mg tds). When first added to treatment with digoxin and frusemide, prazosin was followed within an hour by substantial reductions in systemic arterial, pulmonary arterial, and pulmonary venous pressures in both postures at rest and also during walking. These changes were significantly attenuated after continued treatment. Cardiac output while sitting and standing at rest was reduced in both instances but the response to exercise was unchanged. The pharmacodynamic effects of prazosin in heart failure are explicable in terms of blockade of alpha1 adrenoceptors in arterial resistance and venous capacitance vessels augmented perhaps by lessening of reflex vasoconstriction secondary to the reduction in pulmonary venous pressure. The cause of the attenuation of the acute haemodynamic effects of the drug during sustained treatment is unknown.

Full text

PDF
663

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold S. B., Williams R. L., Ports T. A., Baughman R. A., Benet L. Z., Parmley W. W., Chatterjee K. Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med. 1979 Sep;91(3):345–349. doi: 10.7326/0003-4819-91-3-345. [DOI] [PubMed] [Google Scholar]
  2. Aronow W. S., Lurie M., Turbow M., Whittaker K., Van Camp S., Hughes D. Effect of prazosin vs placebo on chronic left ventricular heart failure. Circulation. 1979 Feb;59(2):344–350. doi: 10.1161/01.cir.59.2.344. [DOI] [PubMed] [Google Scholar]
  3. Aronow W. S., Lurie M., Turbow M., Whittaker K., Van Camp S., Hughes D. Effect of prazosin vs placebo on chronic left ventricular heart failure. Circulation. 1979 Feb;59(2):344–350. doi: 10.1161/01.cir.59.2.344. [DOI] [PubMed] [Google Scholar]
  4. Awan N. A., Evenson M. K., Needham K. E., Mason D. T. Management of refractory congestive heart failure with prazosin. Am Heart J. 1981 Sep;102(3 Pt 2):626–634. doi: 10.1016/0002-8703(81)90755-9. [DOI] [PubMed] [Google Scholar]
  5. Awan N. A., Miller R. R., DeMaria A. N., Maxwell K. S., Neumann A., Mason D. T. Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography. Circulation. 1977 Sep;56(3):346–354. doi: 10.1161/01.cir.56.3.346. [DOI] [PubMed] [Google Scholar]
  6. Awan N. A., Miller R. R., Maxwell K., Mason D. T. Effects of prazosin on forearm resistance and capacitance vessels. Clin Pharmacol Ther. 1977 Jul;22(1):79–84. doi: 10.1002/cpt197722179. [DOI] [PubMed] [Google Scholar]
  7. Awan N. A., Miller R. R., Miller M. P., Specht K., Vera Z., Mason D. T. Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output. Am J Med. 1978 Jul;65(1):146–154. doi: 10.1016/0002-9343(78)90703-9. [DOI] [PubMed] [Google Scholar]
  8. Baughman R. A., Jr, Arnold S., Benet L. Z., Lin E. T., Chatterjee K., Williams R. L. Altered prazosin pharmacokinetics in congestive heart failure. Eur J Clin Pharmacol. 1980 Jun;17(6):425–428. doi: 10.1007/BF00570159. [DOI] [PubMed] [Google Scholar]
  9. Braunwald E. Vasodilator therapy--a physiologic approach to the treatment of heart failure. N Engl J Med. 1977 Aug 11;297(6):331–333. doi: 10.1056/NEJM197708112970609. [DOI] [PubMed] [Google Scholar]
  10. Collier J. G., Lorge R. E., Robinson B. F. Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol. 1978 Jan;5(1):35–44. doi: 10.1111/j.1365-2125.1978.tb01595.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Colucci W. S., Williams G. H., Braunwald E. Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure. Am Heart J. 1981 Sep;102(3 Pt 2):615–621. doi: 10.1016/0002-8703(81)90753-5. [DOI] [PubMed] [Google Scholar]
  12. Colucci W. S., Williams G. H., Braunwald E. Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Ann Intern Med. 1980 Sep;93(3):452–453. doi: 10.7326/0003-4819-93-3-452. [DOI] [PubMed] [Google Scholar]
  13. Colucci W. S., Wynne J., Holman B. L., Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol. 1980 Feb;45(2):337–344. doi: 10.1016/0002-9149(80)90656-6. [DOI] [PubMed] [Google Scholar]
  14. Colucci W. S., Wynne J., Holman B. L., Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol. 1980 Feb;45(2):337–344. doi: 10.1016/0002-9149(80)90656-6. [DOI] [PubMed] [Google Scholar]
  15. Elkayam U., Lejemtel T. H., Mathur M., Ribner H. S., Frishman W. H., Strom J., Sonnenblick E. H. Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol. 1979 Sep;44(3):540–545. doi: 10.1016/0002-9149(79)90409-0. [DOI] [PubMed] [Google Scholar]
  16. Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet. 1980 Jul-Aug;5(4):365–376. doi: 10.2165/00003088-198005040-00004. [DOI] [PubMed] [Google Scholar]
  17. Jaillon P., Rubin P., Yee Y. G., Ball R., Kates R., Harrison D., Blaschke T. Influence of congestive heart failure on prazosin kinetics. Clin Pharmacol Ther. 1979 Jun;25(6):790–794. doi: 10.1002/cpt1979256790. [DOI] [PubMed] [Google Scholar]
  18. Majid P. A., Sharma B., Taylor S. H. Phentolamine for vasodilator treatment of severe heart-failure. Lancet. 1971 Oct 2;2(7727):719–724. doi: 10.1016/s0140-6736(71)92098-8. [DOI] [PubMed] [Google Scholar]
  19. Mason D. T. Symposium on vasodilator and inotropic therapy of heart failure. Symposium perspective. Am J Med. 1978 Jul;65(1):101–105. doi: 10.1016/0002-9343(78)90699-x. [DOI] [PubMed] [Google Scholar]
  20. Miller R. R., Awan N. A., Maxwell K. S., Mason D. T. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med. 1977 Aug 11;297(6):303–307. doi: 10.1056/NEJM197708112970604. [DOI] [PubMed] [Google Scholar]
  21. Packer M., Meller J., Gorlin R., Herman M. V. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. 1979 Mar;59(3):531–539. doi: 10.1161/01.cir.59.3.531. [DOI] [PubMed] [Google Scholar]
  22. Pierpont G. L., Franciosa J. A., Cohn J. N. Effect of prazosin on renal function in congestive heart failure. Clin Pharmacol Ther. 1980 Sep;28(3):335–339. doi: 10.1038/clpt.1980.170. [DOI] [PubMed] [Google Scholar]
  23. Rubin P., Blaschke T. Prazosin protein binding in health and disease. Br J Clin Pharmacol. 1980 Feb;9(2):177–182. doi: 10.1111/j.1365-2125.1980.tb05830.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sharma B., Majid P. A., Meeran M. K., Whitaker W., Taylor S. H. Clinical, electrocardiographic, and haemodynamic effects of digitalis (ouabain) in angina pectoris. Br Heart J. 1972 Jun;34(6):631–637. doi: 10.1136/hrt.34.6.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Silke B., Lakhani Z. M., Taylor S. H. Pharmacokinetic and pharmacodynamic studies with prazosin in chronic heart failure. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):329–335. doi: 10.1097/00005344-198103000-00011. [DOI] [PubMed] [Google Scholar]
  26. Taylor S. H. Pharmacodynamic basis of the use of vasodilators in the treatment of heart failure. Med J Aust. 1980 Jul 26;2 (Suppl 1):19–35. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES